IGF2BP1 and hepatocellular carcinoma: Its reduced expression in patients with HCC acts through post-transcriptional repression of LY6/PLAUR Domain Containing 1 (LYPD1), solidified by IGF2BP1 recognition, diminishing LYPD1 expression and enhancing proliferative and invasive tendencies in patients with HCC [110].